SCHEMBL20715656

SCHEMBL20715656

CC(C)Cc1ccc(NC(=O)[C@@H](N)CCCCN)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 1/20 0.58
▸ THRB P10828 1/20 0.56
▸ SPHK1 Q9NYA1 6/20 0.54
▸ GAA P10253 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ CRHBP P24387 1/20 0.51
▸ CRHR2 Q13324 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ MMP2 P08253 2/20 0.51
▸ SPHK2 Q9NRA0 1/20 0.50
▸ CA12 O43570 1/20 0.49
▸ CA1 P00915 1/20 0.49
▸ CA2 P00918 1/20 0.49
▸ CA4 P22748 1/20 0.49
▸ CA9 Q16790 1/20 0.49
▸ MMP9 P14780 1/20 0.47
▸ S1PR1 P21453 3/20 0.46
▸ S1PR3 Q99500 3/20 0.46
▸ TERT O14746 3/20 0.46
▸ S1PR4 O95977 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19234733 0.86 LTA4H (0.60) LTA4HSPHK1CRHBPCRHR2MMP2
SCHEMBL13258710 0.85 LTA4H (0.62) LTA4HSPHK1MMP2SPHK2MMP9
SCHEMBL20715658 0.83 LTA4H (0.60) LTA4HSPHK1GAAMAPTCRHBP
SCHEMBL20715717 0.83 TRPV1 (0.49) SPHK1GAAMAPTCRHBPCRHR2
SCHEMBL26464130 0.83 LTA4H (0.60) LTA4HSPHK1MAPTMMP2SPHK2
SCHEMBL20715888 0.82 GAA (0.56) LTA4HSPHK1GAAMAPTCRHBP
SCHEMBL20715657 0.81 SPHK1 (0.62) SPHK1GAAMAPTCRHBPCRHR2
SCHEMBL13928680 0.81 NPY4R (0.54) SPHK1GAAMAPTCRHBPCRHR2
SCHEMBL17637516 0.80 LTA4H (0.56) LTA4HSPHK1MMP2SPHK2MMP9
SCHEMBL17661962 0.80 LTA4H (0.56) LTA4HSPHK1MMP2SPHK2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME CDRD VENTURES INC. (CA) 2022-04-14 — — US disclosed
US-11279732-B2 Somatostatin receptor antagonist compounds and methods of using the same CDRD VENTURES INC. (CA) 2022-03-22 — — US disclosed
US-20190040102-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME CDRD VENTURES INC. (CA) 2019-02-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11279732-B2 Somatostatin receptor antagonist compounds and methods of using the same GPR119, SSTR5, SSTR2 LTA4H 2077/4885THRB 73/4885SPHK1 405/4885
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME GPR119, SSTR5, SSTR2 LTA4H 2064/4885THRB 72/4885SPHK1 424/4885
US-20190040102-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME GPR119, SSTR5, SSTR2 LTA4H 2077/4885THRB 73/4885SPHK1 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback